These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 27149627)

  • 21. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole.
    Peláez T; Alcalá L; Alonso R; Martín-López A; García-Arias V; Marín M; Bouza E
    Antimicrob Agents Chemother; 2005 Mar; 49(3):1157-9. PubMed ID: 15728918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. European survey of vancomycin-resistant enterococci in at-risk hospital wards and in vitro susceptibility testing of ramoplanin against these isolates.
    Goossens H; Jabes D; Rossi R; Lammens C; Privitera G; Courvalin P
    J Antimicrob Chemother; 2003 Jun; 51 Suppl 3():iii5-12. PubMed ID: 12801937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms.
    Collins LA; Eliopoulos GM; Wennersten CB; Ferraro MJ; Moellering RC
    Antimicrob Agents Chemother; 1993 Jun; 37(6):1364-6. PubMed ID: 8328787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent.
    Fulco P; Wenzel RP
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):939-45. PubMed ID: 17181409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium.
    Ristow TA; Noskin GA; Warren JR; Peterson LR
    Microb Drug Resist; 1995; 1(4):335-9. PubMed ID: 9158806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ramoplanin: a lipoglycodepsipeptide antibiotic.
    Farver DK; Hedge DD; Lee SC
    Ann Pharmacother; 2005 May; 39(5):863-8. PubMed ID: 15784805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ramoplanin versus methicillin-resistant Staphylococcus aureus: in vitro experience.
    Brumfitt W; Maple PA; Hamilton-Miller JM
    Drugs Exp Clin Res; 1990; 16(8):377-83. PubMed ID: 2097143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of peptidoglycan biosynthesis by ramoplanin.
    Somner EA; Reynolds PE
    Antimicrob Agents Chemother; 1990 Mar; 34(3):413-9. PubMed ID: 2334153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular characterization of vancomycin-resistant Enterococci repopulating the gastrointestinal tract following treatment with a novel glycolipodepsipeptide, ramoplanin.
    Baden LR; Critchley IA; Sahm DF; So W; Gedde M; Porter S; Moellering RC; Eliopoulos G
    J Clin Microbiol; 2002 Apr; 40(4):1160-3. PubMed ID: 11923325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro evaluation of ramoplanin (A16686 or MDL62198). A new depsipeptide complex for potential topical use.
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1989; 12(3):279-82. PubMed ID: 2507218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ambush of Clostridium difficile spores by ramoplanin: activity in an in vitro model.
    Kraus CN; Lyerly MW; Carman RJ
    Antimicrob Agents Chemother; 2015 May; 59(5):2525-30. PubMed ID: 25691641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients.
    Montecalvo MA
    J Antimicrob Chemother; 2003 Jun; 51 Suppl 3():iii31-5. PubMed ID: 12801940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ceftaroline Plus Ampicillin Against Gram-Positive Organisms: Results from E-Test Synergy Assays.
    D'Arezzo S; Mazzarelli A; Venditti C; Nisii C; Petrosillo N; De Giuli C; Vulcano A; Paglia MG; Bordi E; Di Caro A; Taglietti F
    Microb Drug Resist; 2017 Jun; 23(4):507-515. PubMed ID: 27526275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.
    Karlowsky JA; Nichol K; Zhanel GG
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S58-68. PubMed ID: 26316559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of leucine and valine on ramoplanin production by Actinoplanes sp. ATCC 33076.
    Brunati M; Bava A; Marinelli F; Lancini G
    J Antibiot (Tokyo); 2005 Jul; 58(7):473-8. PubMed ID: 16161487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycothiohexides, novel antibiotics produced by "Sebekia" sp. LL-14E605. I. Taxonomy, fermentation and biological evaluation.
    Steinberg DA; Bernan VS; Montenegro DA; Abbanat DR; Pearce CJ; Korshalla JD; Jacobus NV; Petersen PJ; Mroczenski-Wildey MJ; Maiese WM
    J Antibiot (Tokyo); 1994 Aug; 47(8):887-93. PubMed ID: 7928675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy.
    Van Bambeke F
    Curr Opin Investig Drugs; 2006 Aug; 7(8):740-9. PubMed ID: 16955686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of Six Ramoplanin Family Gene Clusters and the Lipoglycodepsipeptide Chersinamycin*.
    Morgan KT; Zheng J; McCafferty DG
    Chembiochem; 2021 Jan; 22(1):176-185. PubMed ID: 32805078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bactericidal activity of ramoplanin against antibiotic-resistant enterococci.
    Johnson CC; Taylor S; Pitsakis P; May P; Levison ME
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2342-5. PubMed ID: 1444316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.